ALAMEDA, Calif., Nov. 5, 2025 /PRNewswire/ -- Penumbra, Inc. (NYSE: PEN), the world's leading thrombectomy company, today reported financial results for the third quarter ended September 30, 2025.
Third Quarter 2025 Financial Results
Total revenue increased to $354.7 million for the third quarter of 2025 compared to $301.0 million for the third quarter of 2024, an increase of 17.8%, or 16.9% in constant currency1. The United States represented 77.5% of total revenue and international represented 22.5% of total revenue for the third quarter of 2025. Revenue from the U.S. increased 21.5% while revenue from our international regions increased 6.6%, or 3.0% in constant currency1. Revenue from sales of our global thrombectomy products grew to $236.4 million in the third quarter of 2025, an increase of 15.8%, or 15.1% in constant currency1 over the same period a year ago, driven primarily by the sales of our U.S. thrombectomy products which increased by 18.5% over the same period a year ago. Revenue from sales of our global embolization and access products grew to $118.3 million for the third quarter of 2025, an increase of 22.0%, or 20.8% in constant currency1 from the same period a year ago, driven primarily by our U.S. embolization and access products which increased by 29.2% from the same period a year ago.
Gross profit for the third quarter of 2025 was $240.4 million, or 67.8% of total revenue compared to $200.3 million, or 66.5% of total revenue, for the third quarter of 2024. Gross margin is impacted by product mix, regional mix, and production initiatives to support demand and create future efficiencies. As such, with favorable product mix, improvement in productivity, and by leveraging our fixed costs on higher volume of new product sales during the year, our gross margin may be positively impacted in the future.
Total operating expenses were $191.6 million, or 54.0% of total revenue for the third quarter of 2025. This compares to total operating expenses of $164.9 million, or 54.8% of total revenue for the third quarter of 2024. R&D expenses were $22.7 million for the third quarter of 2025, compared to $25.2 million for the third quarter of 2024. SG&A expenses were $168.9 million for the third quarter of 2025, compared to $139.7 million for the third quarter of 2024.
Income from operations was $48.8 million for the third quarter of 2025, compared to income from operations of $35.4 million for the third quarter of 2024.
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. |
Updated Full Year 2025 Financial Outlook
The Company is increasing its guidance for 2025 total revenue to a range of $1 billion, 375 million to $1 billion, 380 million, which represents 15% to 16% growth over 2024 revenue of $1 billion, 195 million. The Company maintains guidance for U.S. Thrombectomy growth of 20% to 21% compared to 2024 levels. The Company also maintains guidance for both gross margin and operating margin for full year 2025.
Webcast and Conference Call Information
Penumbra, Inc. will host a conference call to discuss the third quarter 2025 financial results after market close on Wednesday, November 5, 2025 at 4:30 PM Eastern Time. The conference call can be accessed live over the phone by dialing (888) 596-4144 (conference id: 6572573), or the webcast can be accessed on the "Events and Presentations" section under the "Investors" tab of the Company's website at www.penumbrainc.com. The webcast will be available on the Company's website for at least two weeks following the completion of the call.
About Penumbra
Penumbra, Inc., the world's leading thrombectomy company, is focused on developing the most innovative technologies for challenging medical conditions such as ischemic stroke, venous thromboembolism such as pulmonary embolism, and acute limb ischemia. Our broad portfolio, which includes computer assisted vacuum thrombectomy (CAVT), centers on removing blood clots from head-to-toe with speed, safety and simplicity. By pioneering these innovations, we support healthcare providers, hospitals and clinics in more than 100 countries, working to improve patient outcomes and quality of life. For more information, visit www.penumbrainc.com and connect on Instagram, LinkedIn, and X.
Non-GAAP Financial Measures
In addition to financial measures prepared in accordance with U.S. generally accepted accounting principles ("GAAP"), the Company uses the following non-GAAP financial measures in this press release: a) constant currency, b) non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted earnings per share ("EPS") and c) adjusted EBITDA and adjusted EBITDA margin.
Constant Currency. The Company's constant currency revenue disclosures estimate the impact of changes in foreign currency rates on the translation of the Company's current period revenue as compared to the applicable comparable period in the prior year. This impact is derived by taking the current local currency revenue and translating it into U.S. dollars based upon the foreign currency exchange rates used to translate the local currency revenue for the applicable comparable period in the prior year, rather than the actual exchange rates in effect during the current period. It does not include any other effect of changes in foreign currency rates on the Company's results or business.
Non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted EPS. The adjustments to the GAAP financial measures reflect the exclusion of:
Adjusted EBITDA and adjusted EBITDA margin. The Company's adjusted EBITDA reflects the exclusion from GAAP net income (loss) of:
Full reconciliation of these non-GAAP measures to the most comparable GAAP measures is set forth in the tables below.
Our management believes the non-GAAP financial measures disclosed in this press release are useful to investors in assessing the operating performance of our business and provide meaningful comparisons to prior periods and thus a more complete understanding of our business than could be obtained absent this disclosure. Specifically, we consider the change in constant currency revenue as a useful metric as it provides an alternative framework for assessing how our underlying business performed excluding the effect of foreign currency rate fluctuations. We consider non-GAAP operating expenses, non-GAAP income from operations, non-GAAP net income, and non-GAAP diluted EPS useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding non-cash long-lived asset impairment charges related to the impairment of our immersive healthcare asset group, the amortization expense of finite lived intangible assets acquired in connection with the Sixense acquisition, the excess tax benefits associated with share-based compensation arrangements, expenses related to certain litigation matters that we have determined are not a normal or recurring part of our business, including settlement costs and legal fees, and one-time expenses in connection with the wind down of the immersive healthcare business. Further, we consider adjusted EBITDA and adjusted EBITDA margin useful metrics as they provide an alternative framework for assessing how our underlying business performed excluding non-cash operating charges such as stock-based compensation, depreciation and amortization, and impairment charges, non-operating items such as interest income, interest expense, and provision for (benefit from) income taxes, non-recurring litigation related expenses, and one-time expenses in connection with the wind down of the immersive healthcare business.
The non-GAAP financial measures included in this press release may be different from, and therefore may not be comparable to, similarly titled measures used by other companies. These non-GAAP measures should not be considered in isolation or as alternatives to GAAP measures. We urge investors to review the reconciliation of these non-GAAP financial measures to the comparable GAAP financial measures included in this press release, and not to rely on any single financial measure to evaluate our business.
Forward-Looking Statements
Except for historical information, certain statements in this press release are forward-looking in nature and are subject to risks, uncertainties and assumptions about us. Our business and operations are subject to a variety of risks and uncertainties and, consequently, actual results may differ materially from those projected by any forward-looking statements. Factors that could cause actual results to differ from those projected include, but are not limited to: failure to sustain or grow profitability or generate positive cash flows; failure to effectively introduce and market new products; delays in product introductions; significant competition; inability to further penetrate our current customer base, expand our user base and increase the frequency of use of our products by our customers; inability to achieve or maintain satisfactory pricing and margins; manufacturing difficulties; permanent write-downs or write-offs of our inventory or other assets; product defects or failures; unfavorable outcomes in clinical trials; inability to maintain our culture as we grow; fluctuations in foreign currency exchange rates; potential adverse regulatory actions; and the potential impact of any acquisitions, mergers, dispositions, joint ventures or investments we may make. These risks and uncertainties, as well as others, are discussed in greater detail in our filings with the Securities and Exchange Commission ("SEC"), including our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the SEC on February 18, 2025. There may be additional risks of which we are not presently aware or that we currently believe are immaterial which could have an adverse impact on our business. Any forward-looking statements are based on our current expectations, estimates and assumptions regarding future events and are applicable only as of the dates of such statements. We make no commitment to revise or update any forward-looking statements in order to reflect events or circumstances that may change.
Penumbra, Inc. | ||||
Condensed Consolidated Balance Sheets | ||||
(unaudited) | ||||
(in thousands) | ||||
September 30, 2025 | December 31, 2024 | |||
Assets | ||||
Current assets: | ||||
Cash and cash equivalents | $ 321,029 | $ 324,404 | ||
Marketable investments | 149,267 | 15,727 | ||
Accounts receivable, net | 183,430 | 167,668 | ||
Inventories | 432,365 | 406,737 | ||
Prepaid expenses and other current assets | 55,429 | 36,589 | ||
Total current assets | 1,141,520 | 951,125 | ||
Property and equipment, net | 97,730 | 62,641 | ||
Operating lease right-of-use assets | 170,715 | 177,787 | ||
Finance lease right-of-use assets | 26,790 | 28,018 | ||
Intangible assets, net | 6,368 | 6,513 | ||
Goodwill | 166,748 | 165,826 | ||
Deferred taxes | 94,478 | 100,332 | ||
Other non-current assets | 40,020 | 40,939 | ||
Total assets | $ 1,744,369 | $ 1,533,181 | ||
Liabilities and Stockholders' Equity | ||||
Current liabilities: | ||||
Accounts payable | $ 29,821 | $ 31,326 | ||
Accrued liabilities | 124,273 | 112,429 | ||
Current operating lease liabilities | 13,086 | 12,221 | ||
Current finance lease liabilities | 2,423 | 2,369 | ||
Total current liabilities | 169,603 | 158,345 | ||
Non-current operating lease liabilities | 180,313 | 187,068 | ||
Non-current finance lease liabilities | 21,223 | 21,731 | ||
Other non-current liabilities | 14,534 | 15,106 | ||
Total liabilities | 385,673 | 382,250 | ||
Stockholders' equity: | ||||
Common stock | 39 | 38 | ||
Additional paid-in capital | 1,165,195 | 1,096,732 | ||
Accumulated other comprehensive income (loss) | 3,114 | (5,843) | ||
Retained earnings | 190,348 | 60,004 | ||
Total stockholders' equity | 1,358,696 | 1,150,931 | ||
Total liabilities and stockholders' equity | $ 1,744,369 | $ 1,533,181 | ||
Penumbra, Inc. | ||||||||
Condensed Consolidated Statements of Operations | ||||||||
(unaudited) | ||||||||
(in thousands, except share and per share amounts) | ||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
2025 | 2024 | 2025 | 2024 | |||||
Revenue | $ 354,685 | $ 301,039 | $ 1,018,280 | $ 879,097 | ||||
Cost of revenue | 114,269 | 100,733 | 337,971 | 334,823 | ||||
Gross profit | 240,416 | 200,306 | 680,309 | 544,274 | ||||
Operating expenses: | ||||||||
Research and development | 22,677 | 25,205 | 67,972 | 74,773 | ||||
Sales, general and administrative | 168,901 | 139,737 | 482,321 | 426,052 | ||||
Impairment charge | — | — | — | 76,945 | ||||
Total operating expenses | 191,578 | 164,942 | 550,293 | 577,770 | ||||
Income (loss) from operations | 48,838 | 35,364 | 130,016 | (33,496) | ||||
Interest and other income, net | 3,487 | 4,414 | 11,477 | 10,026 | ||||
Income (loss) before income taxes | 52,325 | 39,778 | 141,493 | (23,470) | ||||
Provision for (benefit from) income taxes | 6,474 | 10,251 | 11,149 | (3,799) | ||||
Net income (loss) | $ 45,851 | $ 29,527 | $ 130,344 | $ (19,671) | ||||
Net income (loss) per share: | ||||||||
Basic | $ 1.17 | $ 0.76 | $ 3.36 | $ (0.51) | ||||
Diluted | $ 1.17 | $ 0.75 | $ 3.32 | $ (0.51) | ||||
Weighted average shares outstanding: | ||||||||
Basic | 39,078,378 | 38,610,805 | 38,827,038 | 38,706,809 | ||||
Diluted | 39,302,239 | 39,178,227 | 39,250,680 | 38,706,809 | ||||
Penumbra, Inc. | ||||||||
Reconciliation of GAAP Operating Expenses and GAAP Income (Loss) from Operations to Non-GAAP Operating Expenses and | ||||||||
(unaudited) | ||||||||
(in thousands) | ||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
2025 | 2024 | 2025 | 2024 | |||||
GAAP operating expenses | $ 191,578 | $ 164,942 | $ 550,293 | $ 577,770 | ||||
GAAP operating expenses includes the effect of the following | ||||||||
Impairment charge2 | — | — | — | 76,945 | ||||
Non-recurring litigation related expenses | — | — | — | 4,823 | ||||
Amortization of finite lived intangible assets acquired | — | — | — | 4,759 | ||||
Wind down expenses3 | — | 4,971 | — | 4,971 | ||||
Non-GAAP operating expenses | $ 191,578 | $ 159,971 | $ 550,293 | $ 486,272 | ||||
GAAP income (loss) from operations | $ 48,838 | $ 35,364 | $ 130,016 | $ (33,496) | ||||
GAAP income (loss) from operations includes the effect of the | ||||||||
Impairment charge2 | — | — | — | 76,945 | ||||
Non-recurring litigation related expenses | — | — | — | 4,823 | ||||
Amortization of finite lived intangible assets acquired | — | — | — | 4,759 | ||||
Wind down expenses3 | — | 4,971 | — | 4,971 | ||||
Non-GAAP income from operations | $ 48,838 | $ 40,335 | $ 130,016 | $ 58,002 | ||||
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. | ||||
2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024. | ||||
3Represents one-time expenses that include severance and other costs related to the wind down of the immersive healthcare business during the three and nine months ended September 30, 2024. | ||||
Penumbra, Inc. | ||||||||||||||||
Reconciliation of GAAP Net Income (Loss) and GAAP Diluted EPS to Non-GAAP Net Income and Non-GAAP Diluted EPS1 | ||||||||||||||||
(unaudited) | ||||||||||||||||
(in thousands, except share and per share amounts) | ||||||||||||||||
Three Months Ended September 30, 2025 | Three Months Ended September 30, 2024 | Nine Months Ended | Nine Months Ended | |||||||||||||
Net | Diluted | Net | Diluted | Net | Diluted | Net (loss) | Diluted | |||||||||
GAAP net income (loss) | $ 45,851 | $ 1.17 | $ 29,527 | $ 0.75 | $ 130,344 | $ 3.32 | $ (19,671) | $ (0.51) | ||||||||
GAAP net income (loss) includes the effect of the | ||||||||||||||||
Impairment charge2 | — | — | — | — | — | — | 76,945 | 1.96 | ||||||||
Non-recurring litigation related expenses | — | — | — | — | — | — | 4,823 | 0.12 | ||||||||
Amortization of finite lived intangible assets | — | — | — | — | — | — | 4,759 | 0.12 | ||||||||
Wind down expenses3 | — | — | 4,971 | 0.13 | — | — | 4,971 | 0.13 | ||||||||
Tax effects of the non-GAAP adjustments above4 | — | — | (1,198) | (0.03) | — | — | (22,051) | (0.56) | ||||||||
Excess tax benefits related to stock compensation | (7,754) | (0.20) | (85) | 0.00 | (25,889) | (0.66) | (491) | (0.01) | ||||||||
Non-GAAP net income | $ 38,097 | $ 0.97 | $ 33,215 | $ 0.85 | $ 104,455 | $ 2.66 | $ 49,285 | $ 1.25 | ||||||||
GAAP diluted EPS | $ 1.17 | $ 0.75 | $ 3.32 | $ (0.51) | ||||||||||||
Non-GAAP diluted EPS | $ 0.97 | $ 0.85 | $ 2.66 | $ 1.25 | ||||||||||||
Weighted average shares outstanding used to compute: | ||||||||||||||||
GAAP diluted EPS | 39,302,239 | 39,178,227 | 39,250,680 | 38,706,809 | ||||||||||||
Non-GAAP diluted EPS5 | 39,302,239 | 39,178,227 | 39,250,680 | 39,334,133 | ||||||||||||
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. | ||||
2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024. | ||||
3Represents one-time expenses that include severance and other costs related to the wind down of the immersive healthcare business during the three and nine months ended September 30, 2024. | ||||
4For the three and nine months ended September 30, 2024, management used a combined federal and state tax rate of 24.10% to compute the tax effects of non-GAAP adjustments. | ||||
5For the purposes of calculating non-GAAP diluted EPS for the nine months ended September 30, 2024, non-GAAP diluted weighted average shares outstanding of 39,334,133 were used as the Company had non-GAAP net income in the period. | ||||
Penumbra, Inc. | ||||||||
Reconciliation of GAAP Net Income (Loss) and GAAP Net Income (Loss) Margin to Adjusted EBITDA and Adjusted EBITDA | ||||||||
(unaudited) | ||||||||
(in thousands, except for percentages) | ||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||
2025 | 2024 | 2025 | 2024 | |||||
GAAP net income (loss) | $ 45,851 | $ 29,527 | $ 130,344 | $ (19,671) | ||||
Adjustments to GAAP net income (loss): | ||||||||
Depreciation and amortization expense | 2,488 | 4,148 | 13,010 | 19,314 | ||||
Interest income, net | (4,022) | (3,129) | (10,756) | (9,333) | ||||
Provision for (benefit from) income taxes | 6,474 | 10,251 | 11,149 | (3,799) | ||||
Stock-based compensation expense | 15,932 | 10,940 | 43,951 | 34,069 | ||||
Impairment charge2 | — | — | — | 76,945 | ||||
Non-recurring litigation related expenses | — | — | — | 4,823 | ||||
Wind down expenses3 | — | 4,971 | — | 4,971 | ||||
Adjusted EBITDA | $ 66,723 | $ 56,708 | $ 187,698 | $ 107,319 | ||||
Revenue | $ 354,685 | $ 301,039 | $ 1,018,280 | $ 879,097 | ||||
Adjusted EBITDA | $ 66,723 | $ 56,708 | $ 187,698 | $ 107,319 | ||||
GAAP net income (loss) margin | 12.9 % | 9.8 % | 12.8 % | (2.2) % | ||||
Adjusted EBITDA margin | 18.8 % | 18.8 % | 18.4 % | 12.2 % | ||||
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. | ||||
2Represents charges associated with the impairment of the immersive healthcare asset group during the three months ended June 30, 2024. | ||||
3Represents one-time expenses that include severance and other costs related to the wind down of the immersive healthcare business during the three and nine months ended September 30, 2024. | ||||
Penumbra, Inc. | ||||||||||||||
Reconciliation of Revenue Growth by Geographic Regions to Constant Currency Revenue Growth1 | ||||||||||||||
(unaudited) | ||||||||||||||
(in thousands, except for percentages) | ||||||||||||||
Three Months Ended | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
United States | $ 275,029 | $ 226,326 | $ 48,703 | 21.5 % | $ — | $ 48,703 | 21.5 % | |||||||
International | 79,656 | 74,713 | 4,943 | 6.6 % | (2,689) | 2,254 | 3.0 % | |||||||
Total | $ 354,685 | $ 301,039 | $ 53,646 | 17.8 % | $ (2,689) | $ 50,957 | 16.9 % | |||||||
Nine Months Ended | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
United States | $ 792,707 | $ 654,150 | $ 138,557 | 21.2 % | $ — | $ 138,557 | 21.2 % | |||||||
International | 225,573 | 224,947 | 626 | 0.3 % | (3,169) | (2,543) | (1.1) % | |||||||
Total | $ 1,018,280 | $ 879,097 | $ 139,183 | 15.8 % | $ (3,169) | $ 136,014 | 15.5 % | |||||||
Penumbra, Inc. | ||||||||||||||
Reconciliation of Revenue Change by Product Categories to Constant Currency Revenue Growth1 | ||||||||||||||
(unaudited) | ||||||||||||||
(in thousands, except for percentages) | ||||||||||||||
Three Months Ended | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | $ 236,422 | $ 204,141 | $ 32,281 | 15.8 % | $ (1,444) | $ 30,837 | 15.1 % | |||||||
Embolization and Access | 118,263 | 96,898 | 21,365 | 22.0 % | (1,245) | 20,120 | 20.8 % | |||||||
Total | $ 354,685 | $ 301,039 | $ 53,646 | 17.8 % | $ (2,689) | $ 50,957 | 16.9 % | |||||||
Nine Months Ended | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | $ 693,222 | $ 595,346 | $ 97,876 | 16.4 % | $ (1,682) | $ 96,194 | 16.2 % | |||||||
Embolization and Access | 325,058 | 283,751 | 41,307 | 14.6 % | (1,487) | 39,820 | 14.0 % | |||||||
Total | $ 1,018,280 | $ 879,097 | $ 139,183 | 15.8 % | $ (3,169) | $ 136,014 | 15.5 % | |||||||
Penumbra, Inc. | ||||||||||||||
Reconciliation of Revenue Change by Product Categories and Geographic Regions to Constant Currency Revenue Growth1 | ||||||||||||||
(unaudited) | ||||||||||||||
(in thousands, except for percentages) | ||||||||||||||
Three Months Ended | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | ||||||||||||||
United States | $ 191,994 | $ 162,051 | $ 29,943 | 18.5 % | $ — | $ 29,943 | 18.5 % | |||||||
International | 44,428 | 42,090 | 2,338 | 5.6 % | (1,444) | 894 | 2.1 % | |||||||
Total Thrombectomy | 236,422 | 204,141 | 32,281 | 15.8 % | (1,444) | 30,837 | 15.1 % | |||||||
Embolization and Access | ||||||||||||||
United States | 83,035 | 64,275 | 18,760 | 29.2 % | — | 18,760 | 29.2 % | |||||||
International | 35,228 | 32,623 | 2,605 | 8.0 % | (1,245) | 1,360 | 4.2 % | |||||||
Total Embolization and Access | 118,263 | 96,898 | 21,365 | 22.0 % | (1,245) | 20,120 | 20.8 % | |||||||
Total | $ 354,685 | $ 301,039 | $ 53,646 | 17.8 % | $ (2,689) | $ 50,957 | 16.9 % | |||||||
Nine Months Ended | Reported Change | FX Impact | Constant Currency Change | |||||||||||
2025 | 2024 | $ | % | $ | $ | % | ||||||||
Thrombectomy | ||||||||||||||
United States | $ 568,419 | $ 466,064 | $ 102,355 | 22.0 % | $ — | $ 102,355 | 22.0 % | |||||||
International | 124,803 | 129,282 | (4,479) | (3.5) % | (1,682) | (6,161) | (4.8) % | |||||||
Total Thrombectomy | 693,222 | 595,346 | 97,876 | 16.4 % | (1,682) | 96,194 | 16.2 % | |||||||
Embolization and Access | ||||||||||||||
United States | 224,288 | 188,086 | 36,202 | 19.2 % | — | 36,202 | 19.2 % | |||||||
International | 100,770 | 95,665 | 5,105 | 5.3 % | (1,487) | 3,618 | 3.8 % | |||||||
Total Embolization and Access | 325,058 | 283,751 | 41,307 | 14.6 % | (1,487) | 39,820 | 14.0 % | |||||||
Total | $ 1,018,280 | $ 879,097 | $ 139,183 | 15.8 % | $ (3,169) | $ 136,014 | 15.5 % | |||||||
1See "Non-GAAP Financial Measures" for important information about our use of non-GAAP measures. | ||||
Investor Relations
Penumbra, Inc.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$283.15 |
| Daily Change: | 5.05 1.82 |
| Daily Volume: | 566,138 |
| Market Cap: | US$11.090B |
August 27, 2025 | |
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
